ME01475B - Derivati amino nikotinske iizonikotinske kiseline kao inhibitori dhodh - Google Patents

Derivati amino nikotinske iizonikotinske kiseline kao inhibitori dhodh

Info

Publication number: ME01475B
Authority: ME; Montenegro
Prior art keywords: ylamino; kiselina; nicotinska; group; groups
Prior art date: 2006-12-22

Application number

MEP-2012-104A

Other languages

English (en)

Unknown language (me)

Inventor

Palomino Laria Julio Cesar Castro

Sola Montserrat Erra

Toribio Maria Estrella Lozoya

Romero Eloisa Navarro

Original Assignee

Almirall Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-22

Filing date

2007-12-21

Publication date

2014-04-20

2007-04-23 Priority claimed from ES200701086A external-priority patent/ES2327372B1/es

2007-12-21 Application filed by Almirall Sa filed Critical Almirall Sa

2014-04-20 Publication of ME01475B publication Critical patent/ME01475B/me

Links

239000003112 inhibitor Substances 0.000 title claims description 7
KPIVDNYJNOPGBE-UHFFFAOYSA-N 2-aminonicotinic acid Chemical compound NC1=NC=CC=C1C(O)=O KPIVDNYJNOPGBE-UHFFFAOYSA-N 0.000 title description 3
TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical class OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 title description 3
101150102768 Dhodh gene Proteins 0.000 title 1
125000005843 halogen group Chemical group 0.000 claims 17
150000001875 compounds Chemical class 0.000 claims 16
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 16
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 15
125000001424 substituent group Chemical group 0.000 claims 12
125000001153 fluoro group Chemical group F* 0.000 claims 8
229910052757 nitrogen Inorganic materials 0.000 claims 7
125000004433 nitrogen atom Chemical group N* 0.000 claims 7
125000003545 alkoxy group Chemical group 0.000 claims 6
125000000000 cycloalkoxy group Chemical group 0.000 claims 5
125000000217 alkyl group Chemical group 0.000 claims 4
229910052731 fluorine Inorganic materials 0.000 claims 4
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 2
108010022394 Threonine synthase Proteins 0.000 claims 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
229910052794 bromium Inorganic materials 0.000 claims 2
125000001309 chloro group Chemical group Cl* 0.000 claims 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
102000004419 dihydrofolate reductase Human genes 0.000 claims 2
201000010099 disease Diseases 0.000 claims 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
239000001257 hydrogen Substances 0.000 claims 2
229910052739 hydrogen Inorganic materials 0.000 claims 2
-1 lenercept Proteins 0.000 claims 2
229910052744 lithium Inorganic materials 0.000 claims 2
230000001575 pathological effect Effects 0.000 claims 2
230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 claims 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims 1
JBNWDYGOTHQHOZ-UHFFFAOYSA-N 2-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-1-methylindol-3-yl]-n,n-dimethyl-2-oxoacetamide Chemical compound COC1=CC=2N(C)C=C(C(=O)C(=O)N(C)C)C=2C=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 JBNWDYGOTHQHOZ-UHFFFAOYSA-N 0.000 claims 1
RQVKVJIRFKVPBF-VWLOTQADSA-N 2-[[(2s)-2-amino-3-phenylpropyl]amino]-3-methyl-5-naphthalen-2-yl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C([C@H](N)CNC=1N(C(C(C=2C=C3C=CC=CC3=CC=2)=C(C=2C=CN=CC=2)N=1)=O)C)C1=CC=CC=C1 RQVKVJIRFKVPBF-VWLOTQADSA-N 0.000 claims 1
RCKCJJYMEDONNF-UHFFFAOYSA-N 3-[4-(3-cyclopropyloxyphenyl)-2-fluoroanilino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1NC1=CC=C(C=2C=C(OC3CC3)C=CC=2)C=C1F RCKCJJYMEDONNF-UHFFFAOYSA-N 0.000 claims 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims 1
IFGWYHGYNVGVRB-UHFFFAOYSA-N 5-(2,4-difluorophenoxy)-n-[2-(dimethylamino)ethyl]-1-(2-methylpropyl)indazole-6-carboxamide Chemical compound CN(C)CCNC(=O)C=1C=C2N(CC(C)C)N=CC2=CC=1OC1=CC=C(F)C=C1F IFGWYHGYNVGVRB-UHFFFAOYSA-N 0.000 claims 1
206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
CQSDAMGUBDJYJJ-UHFFFAOYSA-N C(C)OC=1C=C(C=CC1)C1=CC(=C(C=C1)NC1=C(C(=O)O)C=CC=N1)F.FC=1C=C(C=CC1NC1=C(C(=O)O)C=CC=N1)C1=CC(=CC=C1)OC Chemical compound C(C)OC=1C=C(C=CC1)C1=CC(=C(C=C1)NC1=C(C(=O)O)C=CC=N1)F.FC=1C=C(C=CC1NC1=C(C(=O)O)C=CC=N1)C1=CC(=CC=C1)OC CQSDAMGUBDJYJJ-UHFFFAOYSA-N 0.000 claims 1
229940124292 CD20 monoclonal antibody Drugs 0.000 claims 1
102000004631 Calcineurin Human genes 0.000 claims 1
108010042955 Calcineurin Proteins 0.000 claims 1
PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 claims 1
229930105110 Cyclosporin A Natural products 0.000 claims 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
108010036949 Cyclosporine Proteins 0.000 claims 1
108010008165 Etanercept Proteins 0.000 claims 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
ANMATWQYLIFGOK-UHFFFAOYSA-N Iguratimod Chemical compound CS(=O)(=O)NC1=CC=2OC=C(NC=O)C(=O)C=2C=C1OC1=CC=CC=C1 ANMATWQYLIFGOK-UHFFFAOYSA-N 0.000 claims 1
102000019223 Interleukin-1 receptor Human genes 0.000 claims 1
108050006617 Interleukin-1 receptor Proteins 0.000 claims 1
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 1
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
150000001204 N-oxides Chemical class 0.000 claims 1
239000012826 P38 inhibitor Substances 0.000 claims 1
108010027220 PEGylated soluble tumor necrosis factor receptor I Proteins 0.000 claims 1
201000004681 Psoriasis Diseases 0.000 claims 1
201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
108700042805 TRU-015 Proteins 0.000 claims 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
229960002964 adalimumab Drugs 0.000 claims 1
229960003896 aminopterin Drugs 0.000 claims 1
229960004238 anakinra Drugs 0.000 claims 1
239000005557 antagonist Substances 0.000 claims 1
150000001768 cations Chemical class 0.000 claims 1
229960003115 certolizumab pegol Drugs 0.000 claims 1
229960001265 ciclosporin Drugs 0.000 claims 1
229960004414 clomethiazole Drugs 0.000 claims 1
239000013066 combination product Substances 0.000 claims 1
229940127555 combination product Drugs 0.000 claims 1
108010089007 dehydroorotate dehydrogenase Proteins 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
MVCOAUNKQVWQHZ-UHFFFAOYSA-N doramapimod Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 claims 1
229950005521 doramapimod Drugs 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
229960000403 etanercept Drugs 0.000 claims 1
239000011737 fluorine Chemical group 0.000 claims 1
229960001743 golimumab Drugs 0.000 claims 1
229910052736 halogen Inorganic materials 0.000 claims 1
150000002367 halogens Chemical class 0.000 claims 1
229950003909 iguratimod Drugs 0.000 claims 1
229960000598 infliximab Drugs 0.000 claims 1
230000005764 inhibitory process Effects 0.000 claims 1
229950007278 lenercept Drugs 0.000 claims 1
201000006417 multiple sclerosis Diseases 0.000 claims 1
229950005751 ocrelizumab Drugs 0.000 claims 1
229960002450 ofatumumab Drugs 0.000 claims 1
229950010444 onercept Drugs 0.000 claims 1
229950000867 pegsunercept Drugs 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
239000002464 receptor antagonist Substances 0.000 claims 1
229940044551 receptor antagonist Drugs 0.000 claims 1
108010003189 recombinant human tumor necrosis factor-binding protein-1 Proteins 0.000 claims 1
206010039073 rheumatoid arthritis Diseases 0.000 claims 1
229960004641 rituximab Drugs 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
201000000306 sarcoidosis Diseases 0.000 claims 1
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
229960001940 sulfasalazine Drugs 0.000 claims 1
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
229960001967 tacrolimus Drugs 0.000 claims 1
ZMELOYOKMZBMRB-DLBZAZTESA-N talmapimod Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)C=2C(=CC=3N(C)C=C(C=3C=2)C(=O)C(=O)N(C)C)Cl)N1CC1=CC=C(F)C=C1 ZMELOYOKMZBMRB-DLBZAZTESA-N 0.000 claims 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
229960005289 voclosporin Drugs 0.000 claims 1
108010057559 voclosporin Proteins 0.000 claims 1
BICRTLVBTLFLRD-PTWUADNWSA-N voclosporin Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O BICRTLVBTLFLRD-PTWUADNWSA-N 0.000 claims 1
108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 2
102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 2

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)

MEP-2012-104A 2006-12-22 2007-12-21 Derivati amino nikotinske iizonikotinske kiseline kao inhibitori dhodh ME01475B (me)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
ES200603250A ES2319596B1 (es)	2006-12-22	2006-12-22	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES200701086A ES2327372B1 (es)	2007-04-23	2007-04-23	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
PCT/EP2007/011401 WO2008077639A1 (en)	2006-12-22	2007-12-21	Amino nicotinic and isonicotinic acid derivatives as dhodh inhibitors
EP07866261A EP2121614B1 (en)	2006-12-22	2007-12-21	Amino nicotinic and isonicotinic acid derivatives as dhodh inhibitors

Publications (1)

Publication Number	Publication Date
ME01475B true ME01475B (me)	2014-04-20

Family

ID=39319647

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2012-104A ME01475B (me)	2006-12-22	2007-12-21	Derivati amino nikotinske iizonikotinske kiseline kao inhibitori dhodh

Country Status (31)

Country	Link
US (2)	US8258308B2 (sr)
EP (1)	EP2121614B1 (sr)
JP (1)	JP5318776B2 (sr)
KR (1)	KR101435233B1 (sr)
CN (1)	CN101589025B (sr)
AR (1)	AR064444A1 (sr)
AU (1)	AU2007338321B2 (sr)
BR (1)	BRPI0717697B1 (sr)
CA (1)	CA2674512C (sr)
CL (1)	CL2007003666A1 (sr)
CY (1)	CY1113687T1 (sr)
DK (1)	DK2121614T3 (sr)
EC (1)	ECSP099395A (sr)
ES (2)	ES2319596B1 (sr)
HR (1)	HRP20120697T1 (sr)
IL (1)	IL199188A (sr)
ME (1)	ME01475B (sr)
MX (1)	MX2009006408A (sr)
MY (1)	MY153393A (sr)
NO (1)	NO341991B1 (sr)
NZ (1)	NZ577017A (sr)
PE (1)	PE20081846A1 (sr)
PL (1)	PL2121614T3 (sr)
PT (1)	PT2121614E (sr)
RS (1)	RS52514B (sr)
RU (1)	RU2469024C2 (sr)
SI (1)	SI2121614T1 (sr)
TW (1)	TWI405572B (sr)
UY (1)	UY30794A1 (sr)
WO (1)	WO2008077639A1 (sr)
ZA (1)	ZA200903335B (sr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
MX2008014024A (es)	2006-05-04	2008-11-14	Boehringer Ingelheim Int	Formas poliformas.
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
ES2319596B1 (es)	2006-12-22	2010-02-08	Laboratorios Almirall S.A.	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES2327372B1 (es) *	2007-04-23	2010-08-24	Laboratorios Almirall S.A.	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) *	2007-08-10	2009-01-30	Almirall Lab	Nuevos derivados de ácido azabifenilaminobenzoico
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2135610A1 (en) *	2008-06-20	2009-12-23	Laboratorios Almirall, S.A.	Combination comprising DHODH inhibitors and methotrexate
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2362771A1 (en) *	2008-11-07	2011-09-07	4Sc Ag	Combinational therapy comprising dhodh inhibitor and methotrexate for treating autoimmune disease
EP2196465A1 (en)	2008-12-15	2010-06-16	Almirall, S.A.	(3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
EP2226323A1 (en)	2009-02-27	2010-09-08	Almirall, S.A.	New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2239256A1 (en)	2009-03-13	2010-10-13	Almirall, S.A.	Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2228367A1 (en) *	2009-03-13	2010-09-15	Almirall, S.A.	Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
TWI530286B (zh) *	2009-05-04	2016-04-21	帕納特斯製藥格斯有限公司	作為抑制病毒化合物之抗發炎劑
EP2314577A1 (en) *	2009-10-16	2011-04-27	Almirall, S.A.	Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
EP2504002B1 (en)	2009-11-27	2019-10-09	Boehringer Ingelheim International GmbH	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
EP2338888A1 (en)	2009-12-24	2011-06-29	Almirall, S.A.	Imidazopyridine derivatives as JAK inhibitors
EP2360158A1 (en)	2010-02-18	2011-08-24	Almirall, S.A.	Pyrazole derivatives as jak inhibitors
UY33213A (es)	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
EP2380890A1 (en)	2010-04-23	2011-10-26	Almirall, S.A.	New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
US8686048B2 (en)	2010-05-06	2014-04-01	Rhizen Pharmaceuticals Sa	Immunomodulator and anti-inflammatory compounds
EP2394998A1 (en)	2010-05-31	2011-12-14	Almirall, S.A.	3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
EP2397482A1 (en)	2010-06-15	2011-12-21	Almirall, S.A.	Heteroaryl imidazolone derivatives as jak inhibitors
EP2441755A1 (en)	2010-09-30	2012-04-18	Almirall, S.A.	Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2444088A1 (en)	2010-10-22	2012-04-25	Almirall, S.A.	Amino derivatives for the treatment of proliferative skin disorders
EP2444086A1 (en)	2010-10-22	2012-04-25	Almirall, S.A.	Combinations comprising DHODH inhibitors and COX inhibitors
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP2455080A1 (en)	2010-11-23	2012-05-23	Almirall, S.A.	S1P1 receptor agonists for use in the treatment of multiple sclerosis
EP2455081A1 (en)	2010-11-23	2012-05-23	Almirall, S.A.	S1P1 receptor agonists for use in the treatment of crohn's disease
EP2457900A1 (en)	2010-11-25	2012-05-30	Almirall, S.A.	New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en)	2010-11-26	2012-06-13	Almirall, S.A.	Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
US10016402B2 (en) *	2011-02-08	2018-07-10	Children's Medical Center Corporation	Methods for treatment of melanoma
US20140031383A1 (en)	2011-02-08	2014-01-30	Dana-Farber Cancer Institute, Inc.	Methods for treatment of melanoma
EP2489663A1 (en)	2011-02-16	2012-08-22	Almirall, S.A.	Compounds as syk kinase inhibitors
EP2518070A1 (en)	2011-04-29	2012-10-31	Almirall, S.A.	Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en)	2011-04-29	2012-10-31	Almirall, S.A.	Imidazopyridine derivatives as PI3K inhibitors
EP2526945A1 (en)	2011-05-25	2012-11-28	Almirall, S.A.	New CRTH2 Antagonists
EP2527344A1 (en)	2011-05-25	2012-11-28	Almirall, S.A.	Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2548863A1 (en)	2011-07-18	2013-01-23	Almirall, S.A.	New CRTh2 antagonists.
EP2548876A1 (en)	2011-07-18	2013-01-23	Almirall, S.A.	New CRTh2 antagonists
EP2554544A1 (en)	2011-08-01	2013-02-06	Almirall, S.A.	Pyridin-2(1h)-one derivatives as jak inhibitors
EP2594271A1 (en)	2011-11-21	2013-05-22	Almirall, S.A.	2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis.
US20130303462A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
ES2929025T3 (es)	2012-05-14	2022-11-24	Boehringer Ingelheim Int	Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2014060431A1 (en)	2012-10-16	2014-04-24	Almirall, S.A.	Pyrrolotriazinone derivatives as pi3k inhibitors
BR112015009777A2 (pt)	2012-10-31	2017-07-11	Fujifilm Corp	derivado de amina ou sal do mesmo
AR094797A1 (es)	2013-02-15	2015-08-26	Almirall Sa	Derivados de pirrolotriazina como inhibidores de pi3k
AU2014352920A1 (en)	2013-11-22	2016-06-23	Genzyme Corporation	Novel methods for treating neurodegenerative diseases
MX2016013341A (es)	2014-04-11	2017-09-01	Panoptes Pharma Gmbh	Agentes antiinflamatorios como compuestos virostaticos.
HK1231417A1 (zh) *	2014-05-08	2017-12-22	帕诺泰斯制药有限公司	用於治疗眼科疾病和障碍的化合物
WO2016200778A1 (en) *	2015-06-08	2016-12-15	Children's Medical Center Corporation	Methods for treatment of melanoma
WO2016202800A1 (en)	2015-06-16	2016-12-22	Almirall, S.A.	Pyrrolotriazinone derivatives as pi3k inhibitors
BR112018072401A2 (pt)	2016-06-10	2019-02-19	Boehringer Ingelheim International Gmbh	combinações de linagliptina e metformina
WO2018136010A1 (en)	2017-01-20	2018-07-26	Aslan Pharmaceuticals Pte Ltd	Combination therapy
WO2018136009A1 (en)	2017-01-20	2018-07-26	Aslan Pharmaceuticals Pte Ltd	Combination therapy
US11311548B2 (en)	2017-03-02	2022-04-26	Aslan Pharmaceuticals Pte. Ltd.	Cancer therapy
EP3590920B1 (en) *	2017-03-02	2025-05-21	Shanghai Institute of Materia Medica, Chinese Academy of Sciences	2-(substituted benzene matrix) aromatic formate fto inhibitor, preparation method therefor, and applications thereof
EP3589286B1 (en)	2017-03-02	2022-08-03	ASLAN Pharmaceuticals Pte Ltd	Dhodh inhibitor for treating haematological cancer
JP6978251B2 (ja) *	2017-03-03	2021-12-08	アスランファーマシューティカルズピーティーイーリミテッド	がん治療
WO2018222134A1 (en)	2017-06-02	2018-12-06	Aslan Pharmaceuticals Pte Ltd	Cancer therapy
WO2018222135A1 (en)	2017-06-02	2018-12-06	Aslan Pharmaceuticals Pte Ltd	Cancer therapy
IL276918B2 (en)	2018-03-09	2024-10-01	Panoptes Pharma Ges M B H	Ophthalmic formulation comprising albumin and an active compound
JP7126556B2 (ja)	2018-09-28	2022-08-26	富士フイルム株式会社	シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
WO2020130077A1 (ja)	2018-12-21	2020-06-25	国立大学法人北海道大学	多能性幹細胞を除去するための組成物、及び多能性幹細胞の除去方法
EP3750892A1 (en)	2019-06-14	2020-12-16	Yerevan State University	Novel 5-cyclopropyl-furo[3,4-c]pyridine-3,4(1h,5h)-dione 1,1' substituted derivatives and their uses
EP4052760B1 (en)	2019-10-31	2024-03-13	FUJIFILM Corporation	Pyrazine derivative or salt thereof, and use of same
JP7598380B2 (ja) *	2020-07-30	2024-12-11	富士フイルム株式会社	含窒素複素環化合物またはその塩、その利用、およびその中間体
CN116940359A (zh) *	2020-10-15	2023-10-24	亚狮康私人有限公司	用二氢乳清酸脱氢酶（dhodh）抑制剂治疗自身免疫病
EP4228640A1 (en) *	2020-10-15	2023-08-23	ASLAN Pharmaceuticals Pte Ltd	Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor
US20240325373A1 (en) *	2021-06-30	2024-10-03	Ohio State Innovation Foundation	Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpa therapeutic agent
CN118613472A (zh) *	2022-01-31	2024-09-06	新前沿生物公司	基于烟酸酯和烟酰胺核苷的化合物及其衍生物
JP2025506431A (ja) *	2022-02-03	2025-03-11	アスランファーマシューティカルズプライベートリミテッド	Ｄｈｏｄｈ阻害剤多型
WO2025215126A1 (en)	2024-04-12	2025-10-16	Immunic Ag	Synthesis of vidofludimus and its calcium salt

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US529490A (en) *		1894-11-20		hegg-em
EP0040896B1 (en) *	1978-08-22	1984-04-25	Sumitomo Chemical Company, Limited	Synthesis of amides
JPH05331163A (ja) *	1991-03-26	1993-12-14	Kumiai Chem Ind Co Ltd	ピリジン誘導体及び除草剤
DK0672041T3 (da) *	1993-10-01	2002-02-25	Novartis Ag	Farmakologisk aktive pyridinderivater og fremgangsmåder til fremstilling deraf
CA2378713C (en)	1995-06-21	2003-08-12	Asta Medica Aktiengesellschaft	Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
DE19547648A1 (de)	1995-12-20	1997-06-26	Hoechst Ag	Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de)	1996-03-20	1997-09-25	Hoechst Ag	Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9804343D0 (en)	1998-02-27	1998-04-22	Univ Cardiff	Chemical compounds
WO2000076489A2 (en) *	1999-06-10	2000-12-21	Warner-Lambert Company	Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
DK1381356T3 (da)	2001-04-05	2008-09-22	Aventis Pharma Inc	Anvendelse af (z)-z-cyano-3-hydroxy-but-2-enoinsyre-(4-trifluoromethylphenyl) - amide til behandling af multipel sclerose
WO2002102374A1 (en)	2001-06-19	2002-12-27	Merck & Co., Inc.	Amine salt of an integrin receptor antagonist
DE10129703A1 (de)	2001-06-22	2003-01-02	Sofotec Gmbh & Co Kg	Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
MXPA04000224A (es) *	2001-07-10	2005-07-25	4Sc Ag	Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
DE10202940A1 (de)	2002-01-24	2003-07-31	Sofotec Gmbh & Co Kg	Patrone für einen Pulverinhalator
US7258118B2 (en)	2002-01-24	2007-08-21	Sofotec Gmbh & Co, Kg	Pharmaceutical powder cartridge, and inhaler equipped with same
AR042206A1 (es)	2002-11-26	2005-06-15	Novartis Ag	Acidos fenilaceticos y derivados
WO2004056746A1 (en)	2002-12-23	2004-07-08	4Sc Ag	Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EP1581478A1 (en) *	2002-12-23	2005-10-05	4Sc Ag	Dhodh-inhibitors and method for their identification
SE0400234D0 (sv)	2004-02-06	2004-02-06	Active Biotech Ab	New compounds, methods for their preparation and use thereof
AU2005257862A1 (en)	2004-05-21	2006-01-05	The Uab Research Foundation	Compositions and methods relating to pyrimidine synthesis inhibitors
WO2006022442A1 (ja) *	2004-08-24	2006-03-02	Santen Pharmaceutical Co., Ltd.	ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
SG142305A1 (en)	2004-10-19	2008-05-28	Aventis Pharma Inc	Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'- trifluoromethylphenyl)-amide for treating inflammatory bowel disease
MX2007004781A (es) *	2004-10-20	2007-05-11	Applied Research Systems	Derivados de 3-arilamino piridina.
ES2265276B1 (es)	2005-05-20	2008-02-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2319596B1 (es)	2006-12-22	2010-02-08	Laboratorios Almirall S.A.	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
JP5349332B2 (ja)	2007-02-06	2013-11-20	チェルシー・セラピューティクス，インコーポレイテッド	新規化合物、その調製方法、およびその使用
UY31272A1 (es)	2007-08-10	2009-01-30	Almirall Lab	Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en)	2008-06-20	2009-12-23	Laboratorios Almirall, S.A.	Combination comprising DHODH inhibitors and methotrexate
EP2210615A1 (en)	2009-01-21	2010-07-28	Almirall, S.A.	Combinations comprising methotrexate and DHODH inhibitors
EP2230232A1 (en)	2009-03-13	2010-09-22	Almirall, S.A.	Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2239256A1 (en)	2009-03-13	2010-10-13	Almirall, S.A.	Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2228367A1 (en)	2009-03-13	2010-09-15	Almirall, S.A.	Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2314577A1 (en)	2009-10-16	2011-04-27	Almirall, S.A.	Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid

2006
- 2006-12-22 ES ES200603250A patent/ES2319596B1/es not_active Withdrawn - After Issue
2007
- 2007-12-13 UY UY30794A patent/UY30794A1/es active IP Right Grant
- 2007-12-17 TW TW096148215A patent/TWI405572B/zh active
- 2007-12-17 CL CL200703666A patent/CL2007003666A1/es unknown
- 2007-12-19 AR ARP070105721A patent/AR064444A1/es active IP Right Grant
- 2007-12-21 NZ NZ577017A patent/NZ577017A/en unknown
- 2007-12-21 BR BRPI0717697-0A patent/BRPI0717697B1/pt active IP Right Grant
- 2007-12-21 MX MX2009006408A patent/MX2009006408A/es active IP Right Grant
- 2007-12-21 HR HRP20120697TT patent/HRP20120697T1/hr unknown
- 2007-12-21 ES ES07866261T patent/ES2389785T3/es active Active
- 2007-12-21 RS RS20120388A patent/RS52514B/sr unknown
- 2007-12-21 US US12/520,237 patent/US8258308B2/en active Active
- 2007-12-21 ME MEP-2012-104A patent/ME01475B/me unknown
- 2007-12-21 SI SI200731012T patent/SI2121614T1/sl unknown
- 2007-12-21 JP JP2009541921A patent/JP5318776B2/ja active Active
- 2007-12-21 PL PL07866261T patent/PL2121614T3/pl unknown
- 2007-12-21 AU AU2007338321A patent/AU2007338321B2/en active Active
- 2007-12-21 EP EP07866261A patent/EP2121614B1/en active Active
- 2007-12-21 KR KR1020097012714A patent/KR101435233B1/ko active Active
- 2007-12-21 MY MYPI20092607A patent/MY153393A/en unknown
- 2007-12-21 DK DK07866261.6T patent/DK2121614T3/da active
- 2007-12-21 CN CN200780047756XA patent/CN101589025B/zh active Active
- 2007-12-21 RU RU2009127847/04A patent/RU2469024C2/ru active
- 2007-12-21 PT PT07866261T patent/PT2121614E/pt unknown
- 2007-12-21 WO PCT/EP2007/011401 patent/WO2008077639A1/en not_active Ceased
- 2007-12-21 CA CA2674512A patent/CA2674512C/en active Active
2008
- 2008-01-02 PE PE2008000062A patent/PE20081846A1/es active IP Right Grant
2009
- 2009-05-14 ZA ZA200903333A patent/ZA200903335B/xx unknown
- 2009-06-04 IL IL199188A patent/IL199188A/en active IP Right Grant
- 2009-06-09 EC EC2009009395A patent/ECSP099395A/es unknown
- 2009-06-22 NO NO20092380A patent/NO341991B1/no unknown
2012
- 2012-08-06 US US13/567,437 patent/US8691852B2/en active Active
- 2012-09-04 CY CY20121100791T patent/CY1113687T1/el unknown

Also Published As

Publication number	Publication date
CL2007003666A1 (es)	2008-07-04
PE20081846A1 (es)	2008-12-27
DK2121614T3 (da)	2012-09-17
AR064444A1 (es)	2009-04-01
RU2009127847A (ru)	2011-01-27
JP2010513362A (ja)	2010-04-30
BRPI0717697B1 (pt)	2022-05-03
PL2121614T3 (pl)	2012-11-30
JP5318776B2 (ja)	2013-10-16
SI2121614T1 (sl)	2012-10-30
CN101589025A (zh)	2009-11-25
EP2121614A1 (en)	2009-11-25
ES2319596B1 (es)	2010-02-08
MX2009006408A (es)	2009-06-23
ES2319596A1 (es)	2009-05-08
ES2389785T3 (es)	2012-10-31
RU2469024C2 (ru)	2012-12-10
AU2007338321B2 (en)	2012-01-19
US8691852B2 (en)	2014-04-08
CA2674512C (en)	2015-09-08
ZA200903335B (en)	2010-06-30
KR101435233B1 (ko)	2014-08-28
BRPI0717697A2 (pt)	2016-03-22
US20100074898A1 (en)	2010-03-25
CA2674512A1 (en)	2008-07-03
RS52514B (sr)	2013-04-30
MY153393A (en)	2015-02-13
TW200833332A (en)	2008-08-16
TWI405572B (zh)	2013-08-21
CN101589025B (zh)	2012-05-30
AU2007338321A1 (en)	2008-07-03
HK1133014A1 (en)	2010-03-12
HRP20120697T1 (hr)	2012-09-30
PT2121614E (pt)	2012-08-31
CY1113687T1 (el)	2016-06-22
NO341991B1 (no)	2018-03-12
NO20092380L (no)	2009-07-14
EP2121614B1 (en)	2012-06-20
ECSP099395A (es)	2009-07-31
IL199188A (en)	2014-06-30
NZ577017A (en)	2011-12-22
KR20090090352A (ko)	2009-08-25
WO2008077639A1 (en)	2008-07-03
US8258308B2 (en)	2012-09-04
US20120294854A1 (en)	2012-11-22
UY30794A1 (es)	2008-05-31

Publication	Publication Date	Title
ME01475B (me)	2014-04-20	Derivati amino nikotinske iizonikotinske kiseline kao inhibitori dhodh
RU2010108261A (ru)	2011-09-20	Производные азабифениламинобензойной кислоты в качестве ингибиторов dhodh
AR049139A1 (es)	2006-06-28	Compuestos derivados de benzamidas n - heterociclil - sustituidas como activadores de la glucoquinasa (glk), metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso como medicamento en el tratamiento de la diabetes tipo ii.
DK3153020T3 (en)	2019-03-25	SYNERGISTIC FUNGICIDE MIXTURES FOR FERTILIZER IN GRAIN PLANTS
AU2013369670B2 (en)	2017-05-18	Synergistic fungicidal compositions
WO2011138665A1 (en)	2011-11-10	Novel immunomodulator and anti inflammatory compounds
RS67373B1 (sr)	2025-11-28	Sinergističke fungicidne smeše za kontrolu gljivica kod žitarica
WO2004065392A8 (en)	2004-10-07	Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
EP3089587A1 (en)	2016-11-09	Synergistic fungicidal mixtures for fungal control in cereals
BR0315714A (pt)	2005-09-06	Composto, composição para controle de pestes invertebradas, método para controle de pestes invertebradas, composição de aspersão, composição de isca e dispositivo para controle de pestes invertebradas
EA200970557A1 (ru)	2009-12-30	Соединения и композиции в качестве ингибиторов протеинкиназы
NO20071570L (no)	2007-05-23	Fremstilling av TNFR-Ig fusjonsprotein
AU2003259747A1 (en)	2004-03-11	Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP2019506380A5 (sr)	2020-02-06
MXPA03010629A (es)	2004-03-09	Agentes para control de plagas de invertebrados de diamina que contienen un anillo heterociclico, no aromatico.
CN104883886B (zh)	2018-04-20	协同杀真菌组合物
PH12021551626A1 (en)	2022-05-02	Dihydroorotate dehydrogenase inhibitors
MX2020012499A (es)	2021-02-15	Compuestos heterocondensados de piridonas y su uso como inhibidores de la idh.
MX2022002470A (es)	2022-03-22	Inhibidores de dihidroorotato deshidrogenasa sustituidos con urea.
DK1718290T3 (da)	2010-08-02	Sammensætning, som omfatter L-serin, L-isoleucin, folinsyre og sporelementer, til behandling af psoriasis
ATE400179T1 (de)	2008-07-15	Verwendung von pyrimidinetrion-derivaten als acetylcholinesterase-hemmer, diese enthaltende zusammensetzungen und deren verwendungen
Kittleson et al.	2016	Proliferation Signal Inhibitors Prevent Donor-Specific Antibody Production in Sensitized Patients after Heart Transplantation
WO2007113005A3 (en)	2008-01-03	2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors